Severe thrombocytopenia before liver transplantation is associated with delayed recovery of thrombocytopenia regardless of donor type

Table 1 Baseline characteristics of patients

Characteristics (n = 216)	Data
Age at transplant (range), yr	49.1 ± 7.7 (21-66)
Duration posttransplant (range), mo	49.1 ± 29.5 (6-178)
Male/Female (%)	158/58 (73/27)
Donor type (%)
LDLT	169 (78)
CDLT	47 (22)
Indication for transplant (%)
Hepatitis B cirrhosis	113 (52.3)
Hepatitis C cirrhosis	3 (1.4)
Alcoholic cirrhosis	8 (3.7)
Mixed type cirrhosis1	6 (2.8)
Cryptogenic cirrhosis	3 (1.4)
Hepatocellular carcinoma2	75 (34.7)
Autoimmune hepatitis	5 (2.3)
Wilson’s disease	1 (0.5)
Primary biliary cirrhosis	1 (0.5)
Child-Pugh score	9.5 ± 2.2 (5-14)
Cirrhosis complication3 (%)
Ascites	130 (60)
Variceal bleeding	53 (25)
Encephalopathy	81 (38)
SBP	24 (11)
Hepato-renal syndrome	4 (2)
Platelet count, pretransplant (× 103/μL)	58 ± 36 (9-340)
Platelet group (%)
Group 1 (< 30 000/μL)	29 (13)
Group 2 (30 000-50 000/μL)	80 (37)
Gourp 3 (50 000-100 000/μL)	88 (41)
Group 4 (≥ 100 000/μL)	19 (9)
Spleen volume, pretransplant (mm3, n = 193)	1105 ± 636 (128-4858)

¹Alcohol cirrhosis + hepatitis B cirrhosis (n = 5); hepatitis B cirrhosis + hepatitis C cirrhosis (n = 1);

²With hepatitis B virus (n = 70), hepatitis C virus (n = 5);

³Included overlap; SBP: Spontaneous bacterial peritonitis; LDLT: Living donor liver transplantation; CDLT: Cadaveric donor liver transplantation.

Table 2 Univariate and multivariate analysis of clinical factors associated with sustained thrombocytopenia (< 100 000/μL) at 12 mo after the operation

	Sustained thrombocytopenia1		Univariate analysis	Multivariate analysis
	Absent (n = 144)	Present (n = 56)	P	P	OR (95% CI)
Age at transplant (yr)	48.8 ± 7.9	48.6 ± 7.3	ns
Gender			ns
Male	108	40
Female	36	16
Cirrhosis complication, pretransplant			ns
Present	110	44
Absent	34	12
MELD, pretransplant (LDLT)			ns
> 25	20	6
≤ 25	91	38
Child classification, preptranplant			ns
C	75	34
A and B	69	22
Platelet count, pretransplanta			< 0.001	< 0.001	6.314 (2.828-14.095)
Group 1 and 2	56	45
Group 3 and 4	88	11
Spleen volume, pretransplanta			< 0.001	0.004	8.464 (2.001-35.810)
> 2000 mm	3	10
≤ 2000 mm3	124	41
Donor type			ns
LDLT	111	44
CDLT	33	12
Acute rejection			ns
Present	21	5
Absent	123	51
Mycophenolate mofetil use			ns
Yes	44	13
No	100	43
Biliary complication, posttransplant			ns
Present	36	16
Absent	108	40
Portal flow disturbance, posttransplant			ns
Present	3	4
Absent	141	52

^aP < 0.05.

¹Included the patients who survived more than 12 mo. OR: Odds ratio; CI: Confidence interval; HCC: Hepatocellular carcinoma; MELD: Model for end-stage liver disease; ns: Non-specific (P > 0.05).